Asset Transaction Form 8 K

Effective as of the Closing Date (defined below), and subject to the consummation of the Merger (as defined below), Lumos Pharma, Inc. (the "Company" or "Lumos") terminated the Company's 2009 Equity Incentive Plan, 2012 Equity Incentive Plan, the 2010 Non-EmployeeDirectors' Stock Award Plan and the Company's 2010 Employee Stock Purchase Plan, as amended.

In connection with the consummation of the Merger and as a result of the shares of the Company being delisted from Nasdaq, the Company provided notice on December 5, 2024 to Cantor Fitzgerald & Co. ("Cantor") to terminate that certain Controlled Equity Offering^SM Sales Agreement, dated December 30, 2020, by and between the Company and Cantor, as agent, in accordance with the terms therein.